OVERALL SURVIVAL OF PATIENTS POST-TRANSPLANT: STUDY RESULTS FROM TWO PHASE 3 TRIALS ASPIRE AND ENDEAVOR

OVERALL SURVIVAL BENEFIT OF OBINUTUZUMAB OVER RITUXIMAB WHEN COMBINED WITH CHLORAMBUCIL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND COMORBIDITIES: FINAL SURVIVAL ANALYSIS OF THE CLL11 STUDY

TAK-659 PLUS BENDAMUSTINE (+/-RITUXIMAB), GEMCITABINE, LENALIDOMIDE, OR IBRUTINIB IN PATIENTS (PTS) WITH ADVANCED NON-HODGKIN LYMPHOMA (NHL)

LONG-TERM TREATMENT-FREE REMISSION (TFR) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FOLLOWING FRONTLINE (1L) NILOTINIB (NIL): RESULTS FROM ENESTFREEDOM

ADDITION OF VORINOSTAT TO LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MYELOMA DOES NOT IMPROVE OUTCOMES: RESULTS OF THE MYELOMA XI TRIAL

AN UPDATED ANALYSIS OF TISAGENLECLEUCEL IN PEDIATRIC/YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN A US MULTICENTER CLINICAL TRIAL (ENSIGN)

OUTCOMES WITH INOTUZUMAB OZOGAMICIN IN PATIENTS WITH PHILADELPHIA CHROMOSOME–POSITIVE RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA

BOSUTINIB VERSUS IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN THE BFORE TRIAL: 24-MONTH FOLLOW-UP

LONG-TERM TREATMENT-FREE REMISSION (TFR) FOLLOWING SECOND-LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 144-WK RESULTS

RELEVANCE: PHASE III EFFICACY AND SAFETY STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY, FOLLOWED BY RITUXIMAB, IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

PHASE 1/1B STUDY OF PEVONEDISTAT (PEV) AS A SINGLE AGENT OR COMBINED WITH AZACITIDINE (AZA) IN EAST ASIAN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

A PHASE 1 DOSE ESCALATION STUDY OF THE IDH1M INHIBITOR, FT-2102, IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)

HIGH COMPLETE REMISSION RATES WITH ORAL SYK INHIBITOR ENTOSPLETINIB (GS-9973) IN ACUTE MYELOID LEUKEMIA PATIENTS ASSOCIATED WITH HIGH HOXA9/MEIS1 EXPRESSION.

PHASE I STUDY OF UCART19, AN ALLOGENEIC ANTI-CD19 CAR T-CELL PRODUCT, IN HIGH RISK PEDIATRIC PATIENTS WITH CD19+ RELAPSED/REFRACTORY (R/R) B-CELL ALL: PRELIMINARY RESULTS OF PALL STUDY

IMPACT OF TP53-MUTATED CLONE SIZE ON OUTCOME OF RELAPSED/REFRACTORY (R/R) CLL PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB WITHIN THE PHASE 3 MURANO STUDY